EW vs TFX
EW: Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. TFX: Teleflex provides essential, specialty medical technologies used in critical care and surgical procedures to improve patient outcomes.
Side-by-side fundamentals
| Metric | EW | TFX | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $89.79 | $138.83 | |
| Market cap as of 2026-08-24 | $51.8B | $5.9B | |
| P/E as of 2026-08-24 | 53.52 | n/a | |
| PEG as of 2026-08-24 | 3.54 | 0.74 | TFX lower |
| Net margin as of 2026-08-24 | +15.4% | -39.7% | EW higher |
| Gross margin as of 2026-08-24 | +77.8% | +53.8% | EW higher |
| Operating margin as of 2026-08-24 | +18.2% | -11.7% | EW higher |
| ROE as of 2026-08-24 | +9.7% | -31.9% | EW higher |
| ROA as of 2026-08-24 | +7.4% | -14.5% | EW higher |
| Debt / equity as of 2026-08-24 | 0.06 | 0.97 | EW lower |
| Revenue growth (YoY) as of 2026-08-24 | +14.6% | -14.5% | EW higher |
| Revenue CAGR (3y) SEC XBRL | +10.8% | -10.6% | EW higher |
| Dividend yield as of 2026-08-24 | n/a | +0.6% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-24 | 0.85 | 0.81 | |
| 1-year return as of 2026-08-21 close | +10.6% | +11.4% | TFX higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.